home / stock / pepg / pepg news


PEPG News and Press, PepGen Inc. From 11/06/25

Stock Information

Company Name: PepGen Inc.
Stock Symbol: PEPG
Market: NASDAQ
Website: pepgen.com

Menu

PEPG PEPG Quote PEPG Short PEPG News PEPG Articles PEPG Message Board
Get PEPG Alerts

News, Short Squeeze, Breakout and More Instantly...

PEPG - Expected US Company Earnings on Thursday, November 6th, 2025

Avidity Biosciences Inc. (RNA) is expected to report $-1.05 for Q3 2025 Universal Electronics Inc. (UEIC) is expected to report $-0.15 for Q3 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.15 for Q3 2025 Clear Secure Inc. Class A (YOU) is expected to report $0.2...

PEPG - PepGen: Moving To "Hold" Rating On Best Mean Splicing Correction In DM1 Testing

2025-10-29 17:50:28 ET The last time I wrote about PepGen ( PEPG ) it was with respect to a Seeking Alpha article entitled " PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope of Current Treatments ". With respect to this article, I spoke about the potential i...

PEPG - Dyne, PepGen jump as potential beneficiaries of Novartis/Avidity deal

2025-10-27 12:09:02 ET More on Dyne Therapeutics, PepGen Dyne: Accelerated Approval Established Endpoint Sets Stage For DM1 Data In Mid-2026 PepGen: DMD Discontinued, Ways To Go With DM1 Dyne Therapeutics' Valuation Leaves No Room For Error Dyne cut to Perfor...

PEPG - PepGen: DMD Discontinued, Ways To Go With DM1

2025-10-07 18:38:31 ET PepGen Inc. ( PEPG ) has been moving on the recent news that its DM1 treatment has reported strong mean splicing correction data in its phase 1 trials now currently dosing for phase 2. This is good news following the news earlier this year that the phase 2...

PEPG - PepGen Announces Oral Presentations at the 30th Annual International Congress of the World Muscle Society

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company’s data will be presented in two oral...

PEPG - PepGen Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the closing of its previously announced underwritten public...

PEPG - US Companies Moving the Markets, Evening edition
Thu, Sep 25, 2025 as of 4:00 pm ET

A look at the top 10 most actives in the United States Opendoor Technologies Inc (OPEN) rose 10.4% to $9.09 on volume of 362,695,808 shares Datavault AI Inc. (DVLT) rose 28.4% to $0.8348 on volume of 345,799,830 shares PLUS THERAPEUTICS Inc. (PSTV) rose 39.3% to $0.563 on volume of 321,407,...

PEPG - US Companies Moving the Markets, Morning edition
Thu, Sep 25, 2025 as of 10.00 am ET

A look at the top 10 most actives in the United States PLUS THERAPEUTICS Inc. (PSTV) rose 40.1% to $0.566449 on volume of 188,869,548 shares WORK Medical Technology Group LTD (WOK) rose 24.5% to $0.1401 on volume of 174,167,557 shares PepGen Inc. (PEPG) rose 112.6% to $5.6557 on volume of 6...

PEPG - PepGen Inc. Announces $100 Million Public Offering to Advance Clinical Development

2025-09-25 09:20:10 ET PepGen Inc. (Nasdaq: PEPG) , a clinical-stage biotechnology company focused on developing next-generation oligonucleotide therapies, has announced the pricing of an underwritten public offering of 31,250,000 shares of its common stock at $3.20 per share. The offer...

PEPG - PepGen announces pricing of $100M public offering

2025-09-25 00:18:13 ET More on PepGen Seeking Alpha’s Quant Rating on PepGen Historical earnings data for PepGen Financial information for PepGen Read the full article on Seeking Alpha For further details see: PepGen announces pricing of $1...

Previous 10 Next 10